ENDRA Life Sciences Submits De Novo Request for its TAEUS® System Liver Fat Application to the U.S. FDA (Yahoo Finance)

ENDRA Life Sciences Inc. has submitted a De Novo request to the U.S. FDA for its TAEUS system, a non-invasive tool designed to assess fatty liver tissue in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). The system’s liver fat estimates showed a strong correlation with MRI-PDFF, a standard for liver fat measurement. ENDRA’s CEO, Francois Michelon, highlighted TAEUS’s potential to provide a cost-effective alternative to MRI for diagnosing fatty liver disease.